BriaCell Therapeutics Corp. Warrant expiring 2030 (BCTXZ)

About BCTXZ

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Fundamentals

1-day range

$0.1259$0.156

Market cap

$782.1K

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

—

Dividend yield

—

Beta

—

Avg. volume

—

BriaCell Therapeutics Corp. Warrant expiring 2030 Competitors

Chosen by industry and closest market cap.

• BCTXZ

  BriaCell Therapeutics Corp. Warrant expiring 2030

  $0.135

  ▲ 12.31%
  Market cap $782.1KP/E —
  $0.0551$0.52
• BDRX

  Biodexa Pharmaceuticals plc American Depositary Shs

  $0.8351

  ▼ 7.21%
  Market cap $1.06MP/E —
  $0.8303$59.4
• CDT

  CDT Equity Inc. Common Stock

  $1.69

  ▼ 10.37%
  Market cap $1.81MP/E —
  $1.62$2,928
• MTNB

  Matinas Biopharma Holdings Inc. Common Stock

  $0.1966

  ▼ 1.70%
  Market cap $1.93MP/E —
  $0.178$2.14
• OGEN

  Oragenics Inc. Common Stock

  $0.5296

  ▼ 0.08%
  Market cap $2.39MP/E —
  $0.4801$1.45
• SBFM

  Sunshine Biopharma Inc. Common Stock

  $1.16

  ▼ 8.66%
  Market cap $2.48MP/E —
  $1.01$24.3
• ARTL

  Artelo Biosciences Inc. Common Stock

  $0.6619

  ▲ 0.14%
  Market cap $2.59MP/E —
  $0.52$28.14

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

1.42M

Total value held

$198.5K

Institutional holders

4